A citation-based method for searching scientific literature

Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
Times Cited: 203







List of co-cited articles
1245 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
332
36

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
195
28

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
26

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
Lærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, Mette H Jensen, Maria B N Gabe, Alexander H Sparre-Ulrich, Simon Veedfald, Signe Stensen, Amalie R Lanng, Natasha C Bergmann,[...]. Diabetes 2019
73
34

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
353
23

Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
732
22

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
639
22

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
Meena Asmar, Ali Asmar, Lene Simonsen, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Bolette Hartmann, Flemming Dela, Jens Juul Holst, Jens Bülow. Diabetes 2017
64
32


Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
326
20

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
161
20


N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
L S Hansen, A H Sparre-Ulrich, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
56
32

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Mikkel B Christensen, Salvatore Calanna, Jens J Holst, Tina Vilsbøll, Filip K Knop. J Clin Endocrinol Metab 2014
60
30

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
90
20

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Mikkel Christensen, Salvatore Calanna, Alexander H Sparre-Ulrich, Peter L Kristensen, Mette M Rosenkilde, Jens Faber, Francesco Purrello, Gerrit van Hall, Jens J Holst, Tina Vilsbøll,[...]. Diabetes 2015
45
37

Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans.
Meena Asmar, Lene Simonsen, Sten Madsbad, Bente Stallknecht, Jens Juul Holst, Jens Bülow. Diabetes 2010
95
17

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
830
17

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
Anne Nissen, Mikkel Christensen, Filip K Knop, Tina Vilsbøll, Jens J Holst, Bolette Hartmann. J Clin Endocrinol Metab 2014
78
20

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.
Lærke S Gasbjerg, Mikkel B Christensen, Bolette Hartmann, Amalie R Lanng, Alexander H Sparre-Ulrich, Maria B N Gabe, Flemming Dela, Tina Vilsbøll, Jens J Holst, Mette M Rosenkilde,[...]. Diabetologia 2018
52
30


Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
99
16

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
81
19

Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
15

GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release.
A H Sparre-Ulrich, M N Gabe, L S Gasbjerg, C B Christiansen, B Svendsen, B Hartmann, J J Holst, M M Rosenkilde. Biochem Pharmacol 2017
44
34


GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis.
Su-Jin Kim, Cuilan Nian, Subashini Karunakaran, Susanne M Clee, Carlos M Isales, Christopher H S McIntosh. PLoS One 2012
97
15

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
15

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
222
14

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
386
14

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
149
14

Insulin Secretion Depends on Intra-islet Glucagon Signaling.
Berit Svendsen, Olav Larsen, Maria Buur Nordskov Gabe, Charlotte Bayer Christiansen, Mette M Rosenkilde, Daniel J Drucker, Jens Juul Holst. Cell Rep 2018
152
14

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
141
14

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
A H Sparre-Ulrich, L S Hansen, B Svendsen, M Christensen, F K Knop, B Hartmann, J J Holst, M M Rosenkilde. Br J Pharmacol 2016
57
22


MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
147
13

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
13

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Chee W Chia, Olga D Carlson, Wook Kim, Yu-Kyong Shin, Cornelia P Charles, Hee Seung Kim, Denise L Melvin, Josephine M Egan. Diabetes 2009
117
13

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
47
27

The New Biology and Pharmacology of Glucagon.
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
145
12

Evidence of Extrapancreatic Glucagon Secretion in Man.
Asger Lund, Jonatan I Bagger, Nicolai J Wewer Albrechtsen, Mikkel Christensen, Magnus Grøndahl, Bolette Hartmann, Elisabeth R Mathiesen, Carsten P Hansen, Jan H Storkholm, Gerrit van Hall,[...]. Diabetes 2016
104
12


Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.
Salvatore Calanna, Mikkel Christensen, Jens J Holst, Blandine Laferrère, Lise L Gluud, Tina Vilsbøll, Filip K Knop. Diabetes Care 2013
98
12

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
591
12

Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors.
Maria Buur Nordskov Gabe, Alexander Hovard Sparre-Ulrich, Mie Fabricius Pedersen, Lærke Smidt Gasbjerg, Asuka Inoue, Hans Bräuner-Osborne, Bolette Hartmann, Mette Marie Rosenkilde. Biochem Pharmacol 2018
48
25

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Asger Lund, Tina Vilsbøll, Jonatan I Bagger, Jens J Holst, Filip K Knop. Am J Physiol Endocrinol Metab 2011
111
12

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
86
13


GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Nikolaos Mentis, Irfan Vardarli, Lars D Köthe, Jens J Holst, Carolyn F Deacon, Michael Theodorakis, Juris J Meier, Michael A Nauck. Diabetes 2011
109
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.